Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India.
Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, India.
Curr Drug Discov Technol. 2023;20(3):e090323214492. doi: 10.2174/1570163820666230309094233.
Diabetes occurs due to insulin deficiency or less insulin. To manage this condition, insulin administration as well as increased insulin sensitivity is required, but exogeneous insulin cannot replace the sensitive and gentle regulation of blood glucose levels same as β cells of healthy individuals. By considering the ability of regeneration and differentiation of stem cells, the current study planned to evaluate the effect of metformin preconditioned buccal fat pad (BFP) derived mesenchymal stem cells (MSCs) on streptozotocin (STZ) induced diabetes mellitus in Wistar rats.
MATERIALS & METHODS: The disease condition was established by using a diabetes-inducing agent STZ in Wistar rats. Then, the animals were grouped into disease control, blank, and test groups. Only the test group received the metformin-preconditioned cells. The total study period for this experiment was 33 days. During this period, the animals were monitored for blood glucose level, body weight, and food-water intake twice a week. At the end of 33 days, the biochemical estimations for serum insulin level and pancreatic insulin level were performed. Also, histopathology of the pancreas, liver and skeletal muscle was performed.
The test groups showed a decline in the blood glucose level and an increase in the serum pancreatic insulin level as compared to the disease group. No significant change in food and water intake was observed within the three groups, while body weight was significantly reduced in the test group when compared with the blank group, but the life span was increased when compared with the disease group.
In the present study, we concluded that metformin preconditioned buccal fat pad-derived mesenchymal stem cells have the ability to regenerate damaged pancreatic β cells and have antidiabetic activity, and this therapy is a better choice for future research.
糖尿病是由于胰岛素缺乏或胰岛素作用不足引起的。为了控制这种情况，需要进行胰岛素给药和增加胰岛素敏感性，但外源性胰岛素不能像健康个体的β细胞那样对血糖水平进行敏感和温和的调节。考虑到干细胞的再生和分化能力，本研究计划评估二甲双胍预处理颊脂垫（BFP）来源的间充质干细胞（MSCs）对链脲佐菌素（STZ）诱导的 Wistar 大鼠糖尿病的影响。
使用糖尿病诱导剂 STZ 在 Wistar 大鼠中建立疾病状态。然后，将动物分为疾病对照组、空白对照组和实验组。只有实验组接受了二甲双胍预处理的细胞。本实验的总研究期为 33 天。在此期间，每周两次监测动物的血糖水平、体重和食物水摄入量。在第 33 天结束时，进行血清胰岛素水平和胰腺胰岛素水平的生化评估。还对胰腺、肝脏和骨骼肌进行了组织病理学检查。
实验组的血糖水平下降，血清胰腺胰岛素水平升高，与疾病组相比。三组的食物和水摄入量没有明显变化，而实验组的体重与空白组相比明显减轻，但与疾病组相比寿命延长。
在本研究中，我们得出结论，二甲双胍预处理颊脂垫来源的间充质干细胞具有再生受损胰腺β细胞的能力，并具有抗糖尿病活性，这种治疗方法是未来研究的更好选择。
